Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Declines By 17.5%

Plus Therapeutics, Inc. (NASDAQ:PSTV) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 94,000 shares, a drop of 17.5% from the November 30th total of 114,000 shares. Currently, 1.6% of the company’s shares are short sold. Based on an average daily volume of 90,000 shares, the short-interest ratio is presently 1.0 days.

Plus Therapeutics Price Performance

Shares of NASDAQ:PSTV traded up $0.08 during midday trading on Friday, reaching $1.16. 37,204 shares of the company’s stock were exchanged, compared to its average volume of 63,842. The stock has a market cap of $6.84 million, a price-to-earnings ratio of -0.46 and a beta of 0.70. Plus Therapeutics has a fifty-two week low of $0.93 and a fifty-two week high of $2.67. The firm’s 50 day simple moving average is $1.26 and its two-hundred day simple moving average is $1.47.

Institutional Investors Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics at the end of the most recent quarter. 3.28% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PSTV. Ascendiant Capital Markets decreased their target price on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Plus Therapeutics in a report on Tuesday, November 26th.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.